AKRO — Akero Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.48bn
- $3.83bn
- 37
- 26
- 99
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.13 | ||
| Price to Tang. Book | 4.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.51% | ||
| Return on Equity | -27.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Directors
- Mark Iwicki NEC (54)
- Andrew Cheng PRE (54)
- Jonathan Young CFD (51)
- Timothy Rolph CFD (67)
- William White CFO (48)
- Kitty Yale OTH (49)
- Judy Chou IND
- Seth Harrison IND (60)
- Jane Henderson IND (56)
- Tomas Heyman IND (65)
- Graham Walmsley IND (34)
- Yuan Xu IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 24th, 2017
- Public Since
- June 20th, 2019
- No. of Shareholders
- 4
- No. of Employees
- 69
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 79,717,570
- Address
- 601 Gateway Boulevard, Suite 350, SOUTH SAN FRANCISCO, 94080
- Web
- https://akerotx.com/
- Phone
- +1 6504876488
- Contact
- Christina Tartaglia
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AKRO
Q3 2025 Akero Therapeutics Inc Earnings Release
Similar to AKRO
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Akero Therapeutics share price?
As of Today at 19:09 UTC, shares in Akero Therapeutics are trading at $56.19. This share price information is delayed by 15 minutes.
How has the Akero Therapeutics share price performed this year?
Shares in Akero Therapeutics last closed at $56.19 and the price had moved by +140.13% over the past 365 days. In terms of relative price strength the Akero Therapeutics share price has outperformed the S&P500 Index by +112.41% over the past year.
What are the analyst and broker recommendations for Akero Therapeutics?
The overall consensus recommendation for Akero Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Akero Therapeutics dividend yield?
Akero Therapeutics does not currently pay a dividend.
Does Akero Therapeutics pay a dividend?
Akero Therapeutics does not currently pay a dividend.
When does Akero Therapeutics next pay dividends?
Akero Therapeutics does not currently pay a dividend.
How do I buy Akero Therapeutics shares?
To buy shares in Akero Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Akero Therapeutics?
As of the previous close price of $56.19, shares in Akero Therapeutics had a market capitalisation of $4.48bn.
Where are Akero Therapeutics shares listed?
Here are the trading details for Akero Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AKRO
What kind of share is Akero Therapeutics?
Based on an overall assessment of its quality, value and momentum Akero Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Akero Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Akero Therapeutics is $77.00. That is 37.04% above the last closing price of $56.19.
Analysts covering Akero Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.88 for the next financial year.
Find out moreWhat is the trend in the Akero Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akero Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +90.33%.
As of the last closing price of $56.19, shares in Akero Therapeutics were trading +46.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Akero Therapeutics PE Ratio?
The Akero Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $56.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Akero Therapeutics?
Akero Therapeutics' management team is headed by:
- Mark Iwicki - NEC
- Andrew Cheng - PRE
- Jonathan Young - CFD
- Timothy Rolph - CFD
- William White - CFO
- Kitty Yale - OTH
- Judy Chou - IND
- Seth Harrison - IND
- Jane Henderson - IND
- Tomas Heyman - IND
- Graham Walmsley - IND
- Yuan Xu - IND